Engineered Extracellular Vesicle-Based Therapies for Valvular Heart Disease.

ABSTRACT:

Introduction

Valvular heart disease represents a significant burden to the healthcare system, with approximately 5 million cases diagnosed annually in the US. Among these cases, calcific aortic stenosis (CAS) stands out as the most prevalent form of valvular heart disease in the aging population.  CAS is characterized by the progressive calcification of the aortic valve leaflets, leading to valve stiffening. While aortic valve replacement is the standard of care for CAS patients, the long-term durability of prosthetic devices is poor, calling for innovative strategies to halt  or reverse disease progression. Here, we explor the potential use of novel extracellular vesicle (EV)-based nanocarriers for delivering molecular payloads to the affected valve tissue. This approach aims to r

SUBMITTER: Salazar-Puerta AI 

PROVIDER: S-EPMC10550890 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature